Latest news
Did Stronger Q2 Earnings and Lowered 2026 Guidance Just Recast Exelixis' (EXEL) Oncology Narrative? - simplywall.stsimplywall.st · Sat, 08 Aug 2026 18:39:21 GMTAmundi Sells 121,348 Shares of Exelixis, Inc. $EXEL - MarketBeatMarketBeat · Sat, 08 Aug 2026 07:09:18 GMTExelixis (NASDAQ:EXEL) Lowered to "Buy" Rating by Wall Street Zen - MarketBeatMarketBeat · Sat, 08 Aug 2026 06:05:04 GMTExel Composites to host Q2 results briefing online - BitgetBitget · Fri, 07 Aug 2026 11:21:45 GMTExelixis (EXEL) Is Down 6.7% After Cutting 2026 Revenue Outlook Amid Oncology Investment Pivot - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 02:15:00 GMTEXELIXIS INC : LEERINK PARTNERS CUTS TO MARKET PERFORM FROM OUTPERFORM - BitgetBitget · Thu, 06 Aug 2026 20:23:33 GMTExelixis (NASDAQ:EXEL) Rating Lowered to "Market Perform" at Leerink Partners - MarketBeatMarketBeat · Thu, 06 Aug 2026 18:14:21 GMTEXEL Maintained by Truist Securities -- Price Target Lowered to $52.00 - GuruFocusGuruFocus · Thu, 06 Aug 2026 17:56:08 GMT